share_log

Vivos Therapeutics | 8-K: Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics | 8-K: Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics | 8-K:Vivos Therapeutics公布2024年第三季度财务业绩并提供最新运营情况
美股SEC公告 ·  11/14 14:00

Moomoo AI 已提取核心信息

On November 14, 2024, Vivos Therapeutics, Inc., a medical device and technology company, announced its financial results for the third quarter ending September 30, 2024. The company reported a revenue increase of 17% quarter over quarter, with a total revenue of $3.9 million for Q3 and $11.3 million for the nine months ended September 30, 2024. This growth is attributed to higher product sales and service revenue, offset by lower myofunctional therapy revenues. Gross profit also rose to $2.3 million for Q3, with a gross margin increase to 60% compared to 53% in the same period last year. Operating expenses decreased by 8%, reflecting the company's successful cost-cutting initiatives, leading to a 27% reduction in operating loss for the quarter. Vivos anticipates achieving positive cash flow from operations by mid-2025. The company also highlighted...Show More
On November 14, 2024, Vivos Therapeutics, Inc., a medical device and technology company, announced its financial results for the third quarter ending September 30, 2024. The company reported a revenue increase of 17% quarter over quarter, with a total revenue of $3.9 million for Q3 and $11.3 million for the nine months ended September 30, 2024. This growth is attributed to higher product sales and service revenue, offset by lower myofunctional therapy revenues. Gross profit also rose to $2.3 million for Q3, with a gross margin increase to 60% compared to 53% in the same period last year. Operating expenses decreased by 8%, reflecting the company's successful cost-cutting initiatives, leading to a 27% reduction in operating loss for the quarter. Vivos anticipates achieving positive cash flow from operations by mid-2025. The company also highlighted the closing of a $4.3 million registered direct equity offering, which improved its financial position, with cash and cash equivalents totaling $6.3 million as of September 30, 2024. Vivos reported treating over 47,000 patients with its patented oral appliances worldwide and has trained more than 2,000 dentists in the use of The Vivos Method. Additionally, Vivos announced a significant regulatory milestone with the FDA's first-ever 510(k) clearance to treat moderate to severe OSA and snoring in children ages 6 to 17 using its proprietary oral medical device. The company also noted the issuance of new CPT medical codes by the AMA, effective January 1, 2025, which could lead to wider adoption of its devices. Vivos' CEO, Kirk Huntsman, expressed optimism about the company's cost management and growth potential, particularly with recent FDA clearance and new insurance codes. The company will discuss these results and updates in a conference call.
2024年11月14日,医疗器械和科技公司Vivos Therapeutics, Inc.宣布截至2024年9月30日的第三季度财务业绩。公司报告季度营业收入同比增长17%,第三季度营收为390万美元,截至2024年9月30日的九个月营收为1130万美元。这一增长归因于产品销售和服务收入的增加,抵消了咬合功能疗法收入的下降。毛利润也提升至第三季度的230万美元,毛利率增长至60%,相比去年同期的53%。营业费用下降了8%,反映了公司成功的成本削减举措,导致本季度营业亏损减少了27%。Vivos预计到2025年年中实现经营活动现金流为正。公司还强调了完成了一笔430万美元的注册直接股本发行,改善...展开全部
2024年11月14日,医疗器械和科技公司Vivos Therapeutics, Inc.宣布截至2024年9月30日的第三季度财务业绩。公司报告季度营业收入同比增长17%,第三季度营收为390万美元,截至2024年9月30日的九个月营收为1130万美元。这一增长归因于产品销售和服务收入的增加,抵消了咬合功能疗法收入的下降。毛利润也提升至第三季度的230万美元,毛利率增长至60%,相比去年同期的53%。营业费用下降了8%,反映了公司成功的成本削减举措,导致本季度营业亏损减少了27%。Vivos预计到2025年年中实现经营活动现金流为正。公司还强调了完成了一笔430万美元的注册直接股本发行,改善了其财务状况,截至2024年9月30日,现金及现金等价物总额为630万美元。Vivos报告全球治疗逾47,000名患者使用其拥有专利的口腔器械,并已培训了超过2,000名牙医使用Vivos方法。此外,Vivos宣布FDA首次批准510(k)用于儿童6至17岁治疗中重度OSA和打鼾的专有口腔医疗器械的重要监管里程碑。公司还指出美国医学协会(AMA)已发布自2025年1月1日起生效的新CPt医疗代码,可能会导致更广泛地采用其设备。Vivos首席执行官柯克·亨茨曼(Kirk Huntsman)对公司的成本管理和增长潜力表示乐观,特别是在新的FDA批准和新的保险代码下。公司将在电话会议中讨论这些结果和更新。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息